IDH1 and central nervous system cancer: In total, 41 samples of our cohort were inserted into the NOS glioma subgroup, highlighting the need for new biomarkers, in order to be possible to classify gliomas with 1p or 19q deletion and gliomas IDH-wildtype with 1p/19q codeletion.